--- name: the-lancet-infectious-diseases description: Use when targeting The Lancet Infectious Diseases or deciding whether an infectious diseases manuscript fits this venue. Encodes the journal's fit, framing, method-and-evidence bar, house style, official-submission re-check, and desk-reject heuristics. --- # The Lancet Infectious Diseases (the-lancet-infectious-diseases) ## Journal positioning The Lancet Infectious Diseases is one of the most influential specialty journals in the Lancet family, published by Elsevier. It publishes high-impact clinical, epidemiological, and public-health research across all aspects of infectious diseases—bacterial, viral, parasitic, and fungal infections; antimicrobial resistance; vaccines; outbreak science; and health-systems responses to infectious threats. The journal maintains Lancet family editorial standards: pre-registration, CONSORT compliance, global-health equity framing, and a bias toward findings that change clinical practice, public-health policy, or infectious-disease control at population scale. Research that is methodologically competent but locally contained, descriptive without actionable implications, or focused on a narrow pathogen without broader significance will not meet the bar. This skill is a **fit / venue-selection / re-framing** tool. It does not replace the journal's current official submission guidelines. Before submitting, re-check the live author instructions on the Lancet/Elsevier site or submission system. ## When to trigger - The author names The Lancet Infectious Diseases as the target venue for a clinical trial, outbreak investigation, vaccine efficacy study, or AMR epidemiology analysis. - A manuscript on infectious disease has global-health or public-health policy implications and needs framing for the Lancet family editorial culture. - A vaccine, antimicrobial, or antiviral trial has phase III results that could influence WHO or national immunisation or treatment guidelines. - The author needs the journal's desk-reject risks and credible alternatives before submitting. ## Scope & topic fit - Phase III vaccine efficacy or effectiveness trials with population-level public-health implications; immunogenicity studies are accepted when tied to correlates of protection in a practice-relevant context. - Antimicrobial-resistance epidemiology, surveillance, and interventions: burden of AMR, genomic epidemiology of resistant pathogens, stewardship trial results. - Clinical trials of antimicrobial, antiviral, antifungal, or antiparasitic treatments with definitive superiority, non-inferiority, or equivalence results. - Outbreak investigation and epidemic characterisation: natural history, transmission dynamics, clinical severity, and response effectiveness. - Pandemic preparedness and response science: epidemiological modelling with policy implications, health-systems capacity during outbreaks. - Vector-borne disease, neglected tropical diseases, and HIV/AIDS/TB research with global-health equity framing. ## Method & evidence bar - Clinical trials must be pre-registered, CONSORT-compliant in full, and powered for clinically or epidemiologically meaningful primary endpoints; for vaccine trials, the primary endpoint should relate to clinical outcomes or established immune correlates of protection. - Observational and epidemiological studies require STROBE adherence; genomic-epidemiology studies should follow STREGA or equivalent molecular-epidemiology reporting standards. - Systematic reviews and meta-analyses of ID trials require PRISMA, PROSPERO registration, and GRADE evidence grading, especially for WHO guideline-supporting reviews. - Outbreak investigations should include case definitions, attack rates with confidence intervals, environmental and laboratory confirmation, and a policy-relevant interpretation. - Epidemiological models must state assumptions explicitly, validate against observed data, and provide uncertainty ranges; code and data should be publicly available. - Ethics approval, informed consent, national and institutional review (especially for work in LMICs), and data-sharing statements are mandatory. ## Structure & house style - The Lancet Infectious Diseases uses the Lancet family structured abstract (background, methods, findings, interpretation) with a mandatory funding statement at the end of the abstract. - An "Added value of this study" panel (what is already known, what this study adds) is required and must be precise about the evidence gap this study closes. - Opening paragraphs must establish the global burden, policy context, or clinical unmet need—a local epidemiological context without international relevance is insufficient. - Epidemiological figures: maps with burden data, epidemic curves, and forest plots for meta-analyses are standard; colour-blind-accessible palettes expected. - Statistical reporting must include absolute as well as relative effect measures; vaccine efficacy should be reported with confidence intervals and the corresponding absolute risk reduction. - Data and code availability for modelling studies and genomic analyses should specify the repository and accession identifier. ## Official-submission checklist - Before giving submission-ready advice, read `../../resources/source-basis.md` and `../../resources/official-source-map.md`; start from the official source anchors for this journal family, then cite the current journal-specific page you checked. - Search the live site for "The Lancet Infectious Diseases information for authors" and follow the current Elsevier/Lancet version. - Re-check article type, current word and figure limits, and "Added value" panel format. - Confirm trial or review registration number, ethics approval reference, and informed-consent statement. - Submit CONSORT (trials), PRISMA (reviews), STROBE (observational), or STREGA (molecular epidemiology) checklist as appropriate. - Re-check data-sharing statement; for genomic-epidemiology and modelling studies, specify repository accession or DOI. - Re-check competing-interests declaration, funding disclosure (especially for vaccine-industry-funded trials), ICMJE author-contribution statement, and AI-use disclosure. - Re-check open-access/APC, licensing, and preprint policy. - If the live official instructions conflict with this skill, the official instructions win. ## Pre-submission self-check - [ ] One sentence stating which clinical practice, public-health guideline, or outbreak-control policy this finding changes or informs. - [ ] The "Added value" panel is specific: what question was unanswered before this study, and what is now established. - [ ] The global-health or policy framing is data-supported: burden estimates, LMIC context, or WHO-relevance are documented, not asserted. - [ ] Reporting-guideline checklist is complete and ready to upload; trial registration and ethics approval are cited in the methods. - [ ] For genomic or modelling studies, code and data are deposited with a repository identifier. - [ ] Competing interests, especially industry funding of vaccine or treatment trials, are fully disclosed with sponsor-independence statement. ## Common desk-reject triggers - Clinical study on a pathogen or intervention with demonstrated local significance but no argument for broader policy or public-health impact. - CONSORT non-compliance or absent trial registration; primary endpoint switched without documented protocol amendment. - Epidemiological or modelling study without code or data availability, or whose assumptions are not validated against real-world data. - "Added value" panel that is generic or duplicates what existing reviews have already established. - Outbreak report with descriptive epidemiology only, no clinical management, control-intervention, or pathogen-characterisation data that advances beyond a standard line-list analysis. - Vaccine immunogenicity study without clinical efficacy correlates or policy-relevant comparator. ## Re-routing decision - ID findings with broader general medicine framing → `the-lancet`. - Mechanistic host-pathogen biology without clinical trial anchor → `cell-host-and-microbe` or `nature-microbiology`. - Vaccine trial with predominantly immunological rather than clinical primary endpoint → `nature-medicine`. - AMR clinical trial with global policy framing → retain here; AMR basic microbiology → specialist microbiology journals. - HIV, TB, malaria trials of international clinical significance → `the-lancet` if they meet the flagship practice-change bar. ## Output format ```text [Fit] High / Medium / Low (one-line reason) [Target] The Lancet Infectious Diseases [Topic tags] <2–3 closest topics> [Method/evidence] [Top risk] [Official items to re-check]
[Re-route suggestion] ```